- Home
- CR vs ROIV Comparison
CR vs ROIV Comparison
Compare CR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- ROIV
- Stock Information
- Founded
- CR 1855
- ROIV 2014
- Country
- CR United States
- ROIV United Kingdom
- Employees
- CR N/A
- ROIV N/A
- Industry
- CR Metal Fabrications
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- ROIV Health Care
- Exchange
- CR Nasdaq
- ROIV Nasdaq
- Market Cap
- CR 10.4B
- ROIV 8.6B
- IPO Year
- CR N/A
- ROIV N/A
- Fundamental
- Price
- CR $180.12
- ROIV $17.23
- Analyst Decision
- CR Strong Buy
- ROIV Strong Buy
- Analyst Count
- CR 5
- ROIV 8
- Target Price
- CR $222.20
- ROIV $19.94
- AVG Volume (30 Days)
- CR 264.1K
- ROIV 7.5M
- Earning Date
- CR 10-27-2025
- ROIV 11-11-2025
- Dividend Yield
- CR 0.51%
- ROIV N/A
- EPS Growth
- CR 44.57
- ROIV N/A
- EPS
- CR 6.02
- ROIV N/A
- Revenue
- CR $2,227,200,000.00
- ROIV $23,233,000.00
- Revenue This Year
- CR $10.69
- ROIV N/A
- Revenue Next Year
- CR $10.98
- ROIV $200.91
- P/E Ratio
- CR $29.97
- ROIV N/A
- Revenue Growth
- CR 18.63
- ROIV N/A
- 52 Week Low
- CR $127.04
- ROIV $8.73
- 52 Week High
- CR $203.89
- ROIV $17.13
- Technical
- Relative Strength Index (RSI)
- CR 48.98
- ROIV 81.19
- Support Level
- CR $175.03
- ROIV $15.91
- Resistance Level
- CR $182.76
- ROIV $17.13
- Average True Range (ATR)
- CR 4.13
- ROIV 0.49
- MACD
- CR 0.32
- ROIV 0.02
- Stochastic Oscillator
- CR 64.74
- ROIV 98.90
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.